12:00 AM
 | 
Nov 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

tgAAVCF: Phase I/II

TGEN presented data from 23 patients in which administration of tgAAVCF to one sinus resulted in decreased IL-8 levels, which the company said could reduce inflammation associated with CF once...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >